
    
      Phase II non comparative study, assessing the safety (primarily cardiac safety) and efficacy
      in patients with locally advanced or metastatic HER2/neu negative breast cancer not yet
      treated with chemotherapy for metastatic disease.

      Myocet and Taxotere will be given for a maximum of 6 cycles. Endpoints: cardiotoxicity (left
      ventricular ejection fraction decrease and/or symptoms of heart failure), serious other
      toxicity, disease progression.
    
  